Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options-a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference

Paulus Kirchhof*, Gregory Y. H. Lip, Isabelle C. Van Gelder, Jeroen Bax, Elaine Hylek, Stefan Kaab, Ulrich Schotten, Karl Wegscheider, Giuseppe Boriani, Axel Brandes, Michael D. Ezekowitz, Hans-Christoph Diener, Laurent Haegeli, Hein Heidbuchel, Deirdre A. Lane, Luis Mont, Stephan Willems, Paul Dorian, Maria Aunes-Jansson, Carina Blomstrom-LundqvistMaria Borentain, Stefanie Breitenstein, Martina Brueckmann, Nilo Cater, Andreas Clemens, Dobromir Dobrev, Sergio Dubner, Nils G. Edvardsson, Leif Friberg, Andreas Goette, Michele Gulizia, Robert Hatala, Jenny Horwood, Lukas Szumowski, Lukas Kappenberger, Josef Kautzner, Angelika Leute, Trudie Lobban, Ralf Meyer, Jay Millerhagen, John Morgan, Felix Muenzel, Michael Nabauer, Christoph Baertels, Michael Oeff, Dieter Paar, Juergen Polifka, Ursula Ravens, Ludger Rosin, Wim Stegink, Gerhard Steinbeck, Panos Vardas, Alphons Vincent, Maureen Walter, Guenter Breithardt, A. John Camm

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

147 Citations (Web of Science)

Abstract

While management of atrial fibrillation (AF) patients is improved by guideline-conform application of anticoagulant therapy, rate control, rhythm control, and therapy of accompanying heart disease, the morbidity and mortality associated with AF remain unacceptably high. This paper describes the proceedings of the 3rd Atrial Fibrillation NETwork (AFNET)/European Heart Rhythm Association (EHRA) consensus conference that convened over 60 scientists and representatives from industry to jointly discuss emerging therapeutic and diagnostic improvements to achieve better management of AF patients. The paper covers four chapters: (i) risk factors and risk markers for AF; (ii) pathophysiological classification of AF; (iii) relevance of monitored AF duration for AF-related outcomes; and (iv) perspectives and needs for implementing better antithrombotic therapy. Relevant published literature for each section is covered, and suggestions for the improvement of management in each area are put forward. Combined, the propositions formulate a perspective to implement comprehensive management in AF.
Original languageEnglish
Pages (from-to)8-27
JournalEP Europace
Volume14
Issue number1
DOIs
Publication statusPublished - Jan 2012

Keywords

  • atrial fibrillation
  • management
  • outcomes
  • antithrombotic therapy
  • rate control
  • rhythm control
  • risk factors
  • early therapy

Cite this